Abstract 1653P
Background
The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But excess IPFD, leads to a wide array of diseases, including but not limited to diabetes, pancreatitis, and pancreatic cancer (PC). Remarkably, PC patients with excessive intra-pancreatic fat accumulation are commonly associated with a poor prognosis compared to those with minimal IPFD. However, the interaction between tumor and IPFD remains elusive. Here, we evaluated the pancreatic fat infiltration in normal people and patients with PC respectively, and explored how intra-pancreatic fat accelerates tumor progression.
Methods
Magnetic resonance imaging (MRI) and clinical biopsy specimens were used to assess the degree of pancreatic fat infiltration in PC patients and healthy control individuals. The KC, KPC, KCO, and AAV8-ADIPOQ-DTA mice were established to demonstrate that IPFD promoted tumor progression. The single-nucleus sequencing of pancreatic fat tissue and proteomic of PC cell lines were performed to identify the mechanism of interaction between cancer cells and adipocytes.
Results
We found that patients with PC presented excess intra-pancreatic fat deposition more frequently than control individuals, and the degree of fat infiltration was positively correlated with the tumor size of PC patients. High-fat diet KPC mice or KCO mice showed a higher degree of IPFD, which contributed to tumor growth and low survival rates of mice. Besides, the expression of uncoupling protein 1 (UCP1) was upregulated in PC patients or spontaneous tumor mice compared to normal controls. Constantly, the single-nucleus sequencing of pancreatic fat tissue of PC patients demonstrated the increase in thermogenesis features. Specifically, we revealed that PC cells improved the thermogenesis of intra-pancreatic adipose tissue, which in turn promoted PC cell proliferation.
Conclusions
We demonstrated that excess intra-pancreatic fat infiltration fuels the progression of PC, and selectively eliminating fat in the pancreas inhibits tumor growth. Mechanistically, PC cells promote the browning of adipocytes, and then the activated adipocytes enhance the proliferation and migration of cancer cells in response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
PUMCH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1589P - Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Presenter: Niels Guchelaar
Session: Poster session 22
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22